Merck profit beats, but Keytruda sales fail to impress
Merck & Co beat quarterly profit estimates on Friday as sales of its blockbuster drug Keytruda overtook rival Bristol-Myers Squibb’s Opdivo, but that was not enough for investors who expected bigger gains in market share for the cancer therapy.
